{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:38:19Z","timestamp":1791041899602,"version":"4.1.0"},"reference-count":32,"publisher":"Japan Endocrine Society","issue":"2","funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1507\/endocrj.ej25-0116","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:07:44Z","timestamp":1763762864000},"page":"229-241","source":"Crossref","is-referenced-by-count":1,"title":["Long-term effectiveness and safety of daily growth hormone therapy in Japanese children with Noonan syndrome: a post-marketing surveillance study"],"prefix":"10.1507","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1810-9894","authenticated-orcid":false,"given":"Koji","family":"Muroya","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kanagawa Children\u2019s Medical Center, Yokohama 232-0066, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4466-1559","authenticated-orcid":false,"given":"Masanobu","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nutrition and Endocrinology, Research Institute, Osaka Women\u2019s and Children\u2019s Hospital, Izumi 594-1101, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9756-3744","authenticated-orcid":false,"given":"Hiroyuki","family":"Yamagishi","sequence":"additional","affiliation":[{"name":"Division of Pediatric Cardiology, Department of Pediatrics, Keio University School of Medicine, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6146-6394","authenticated-orcid":false,"given":"Takaaki","family":"Endo","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Novo Nordisk Pharma Ltd, Tokyo 100-0005, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Pietropoli","sequence":"additional","affiliation":[{"name":"Department of Rare Endocrine Disorders, Novo Nordisk Health Care AG, 8058 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Ferran","sequence":"additional","affiliation":[{"name":"Qualiance ApS, 1663 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3429-3246","authenticated-orcid":false,"given":"Reiko","family":"Horikawa","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo 157-8535, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Romano AA, Dana K, Bakker B, Davis DA, Hunold JJ, et al. (2009) Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone. J Clin Endocrinol Metab 94: 2338\u20132344.","DOI":"10.1210\/jc.2008-2094"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, et al. (2007) Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 39: 70\u201374.","DOI":"10.1038\/ng1926"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Lee CK, Chang BS, Hong YM, Yang SW, Lee CS, et al. (2001) Spinal deformities in Noonan syndrome: a clinical review of sixty cases. J Bone Joint Surg Am 83: 1495\u20131502.","DOI":"10.2106\/00004623-200110000-00006"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Noonan JA, Raaijmakers R, Hall BD (2003) Adult height in Noonan syndrome. Am J Med Genet A 123a: 68\u201371.","DOI":"10.1002\/ajmg.a.20502"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Kruszka P, Porras AR, Addissie YA, Moresco A, Medrano S, et al. (2017) Noonan syndrome in diverse populations. Am J Med Genet A 173: 2323\u20132334.","DOI":"10.1002\/ajmg.a.38362"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Jongmans MC, van der Burgt I, Hoogerbrugge PM, Noordam K, Yntema HG, et al. (2011) Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. Eur J Hum Genet 19: 870\u2013874.","DOI":"10.1038\/ejhg.2011.37"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Noordam C, Peer PG, Francois I, De Schepper J, van den Burgt I, et al. (2008) Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11. Eur J Endocrinol 159: 203\u2013208.","DOI":"10.1530\/EJE-08-0413"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ogawa M, Moriya N, Ikeda H, Tanae A, Tanaka T, et al. (2004) Clinical evaluation of recombinant human growth hormone in Noonan syndrome. Endocr J 51: 61\u201368.","DOI":"10.1507\/endocrj.51.61"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Osio D, Dahlgren J, Wikland KA, Westphal O (2005) Improved final height with long-term growth hormone treatment in Noonan syndrome. Acta Paediatr 94: 1232\u20131237.","DOI":"10.1111\/j.1651-2227.2005.tb02081.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Noonan JA, Kappelgaard AM (2015) The efficacy and safety of growth hormone therapy in children with noonan syndrome: a review of the evidence. Horm Res Paediatr 83: 157\u2013166.","DOI":"10.1159\/000369012"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Dahlgren J, Noordam C (2022) Growth, endocrine features, and growth hormone treatment in Noonan syndrome. J Clin Med 11: 2034.","DOI":"10.3390\/jcm11072034"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Jorge AAL, Edouard T, Maghnie M, Pietropoli A, Kelepouris N, et al. (2022) Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status. Endocr Connect 11: e210615.","DOI":"10.1530\/EC-21-0615"},{"key":"13","unstructured":"13 (2017) Norditropin highlights of prescribing information. US Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021148s049lbl.pdf accessed on April 20, 2023."},{"key":"14","unstructured":"14 (2022) Report on investigation results. Pharmaceuticals and medical devices agency. https:\/\/www.pmda.go.jp\/files\/000246397.pdf accessed on April 20, 2023."},{"key":"15","unstructured":"15 (2022) Norditropin FlexPro 5mg\/1.5mL, 10mg\/1.5mL, 15mg\/1.5mL SmPC. Electronic Medicine Compendium. https:\/\/www.medicines.org.uk\/EMC\/medicine\/2760\/SPC\/Norditropin+SimpleXx+5+mg+1.5+mL%2c+10+mg+1.5+mL%2c+15+mg+1.5+mL%3b+Norditropin+NordiFlex+15+mg+1.5+mL accessed on November 30, 2024."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Horikawa R, Ogata T, Matsubara Y, Yokoya S, Ogawa Y, et al. (2020) Long-term efficacy and safety of two doses of Norditropin(<sup>\u00ae<\/sup>) (somatropin) in Noonan syndrome: a 4-year randomized, double-blind, multicenter trial in Japanese patients. Endocr J 67: 803\u2013818.","DOI":"10.1507\/endocrj.EJ19-0371"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Ozono K, Ogata T, Horikawa R, Matsubara Y, Ogawa Y, et al. (2018) Efficacy and safety of two doses of Norditropin(<sup>\u00ae<\/sup>) (somatropin) in short stature due to Noonan syndrome: a 2-year randomized, double-blind, multicenter trial in Japanese patients. Endocr J 65: 159\u2013174.","DOI":"10.1507\/endocrj.EJ17-0313"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18 World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310: 2191\u20132194.","DOI":"10.1001\/jama.2013.281053"},{"key":"19","unstructured":"19 (2015) Guidelines for Good Pharmacoepidemiology Practices (GPP). International Society for Pharmacoepidemiology. https:\/\/www.pharmacoepi.org\/resources\/policies\/guidelines-08027\/#Top accessed on July 17, 2023."},{"key":"20","unstructured":"20 (2016) Guideline for good clinical practice E6(R2). European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-good-clinical-practice-e6r2-step-5-revision-2_en.pdf accessed on April 30, 2025."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Kratz CP, Franke L, Peters H, Kohlschmidt N, Kazmierczak B, et al. (2015) Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. Br J Cancer 112: 1392\u20131397.","DOI":"10.1038\/bjc.2015.75"},{"key":"22","unstructured":"22 (2024) Norditropin FlexPro 5 mg\/1.5 ml solution for injection in pre-filled pen. Novo Nordisk Limited. https:\/\/www.medicines.org.uk\/emc\/product\/11755\/pil#gref accessed on November 11, 2024."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Cappa M, d\u2019Aniello F, Digilio MC, Gagliardi MG, Minotti C, et al. (2024) Noonan syndrome growth charts and genotypes: 15-year longitudinal single-centre study. Horm Res Paediatr 2024: 1\u201313.","DOI":"10.1159\/000540092"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Tamburrino F, Mazzanti L, Gibertoni D, Schiavariello C, Perri A, et al. (2024) Impact of pubertal timing on growth progression and final height in subjects affected by RASopathies. Front Endocrinol (Lausanne) 15: 1531545.","DOI":"10.3389\/fendo.2024.1531545"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Rezende RC, Noronha RM, Keselman A, Quedas EPS, Dantas NCB, et al. (2022) Delayed puberty phenotype observed in noonan syndrome is more pronounced in girls than boys. Horm Res Paediatr 95: 51\u201361.","DOI":"10.1159\/000522670"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Tamburrino F, Gibertoni D, Rossi C, Scarano E, Perri A, et al. (2015) Response to long-term growth hormone therapy in patients affected by RASopathies and growth hormone deficiency: patterns of growth, puberty and final height data. Am J Med Genet A 167a: 2786\u20132794.","DOI":"10.1002\/ajmg.a.37260"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Rohrer TR, Abuzzahab J, Backeljauw P, Birkeg\u00e5rd AC, Blair J, et al. (2020) Long-term effectiveness and safety of childhood growth hormone treatment in noonan syndrome. Horm Res Paediatr 93: 380\u2013395.","DOI":"10.1159\/000512429"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Jeong I, Kang E, Cho JH, Kim GH, Lee BH, et al. (2016) Long-term efficacy of recombinant human growth hormone therapy in short-statured patients with Noonan syndrome. Ann Pediatr Endocrinol Metab 21: 26\u201330.","DOI":"10.6065\/apem.2016.21.1.26"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Romano A, Kaski JP, Dahlgren J, Kelepouris N, Pietropoli A, et al. (2022) Cardiovascular safety of growth hormone treatment in Noonan syndrome: real-world evidence. Endocr Connect 11: e210549.","DOI":"10.1530\/EC-21-0549"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 MacFarlane CE, Brown DC, Johnston LB, Patton MA, Dunger DB, et al. (2001) Growth hormone therapy and growth in children with Noonan\u2019s syndrome: results of 3 years\u2019 follow-up. J Clin Endocrinol Metab 86: 1953\u20131956.","DOI":"10.1210\/jcem.86.5.7468"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Linglart L, Gelb BD (2020) Congenital heart defects in Noonan syndrome: diagnosis, management, and treatment. Am J Med Genet C Semin Med Genet 184: 73\u201380.","DOI":"10.1002\/ajmg.c.31765"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Prendiville TW, Gauvreau K, Tworog-Dube E, Patkin L, Kucherlapati RS, et al. (2014) Cardiovascular disease in Noonan syndrome. Arch Dis Child 99: 629\u2013634.","DOI":"10.1136\/archdischild-2013-305047"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/2\/73_EJ25-0116\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:25:19Z","timestamp":1770434719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/2\/73_EJ25-0116\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej25-0116","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"EJ25-0116"}}